Alphabet’s AI drug-discovery venture is reportedly seeking new financing, but discussions remain unfinished while its programs are still in preclinical development.
Isomorphic Labs, the Alphabet venture applying artificial intelligence to drug design, is in talks for new financing, Bloomberg reported November 4, citing people familiar with the matter. The discussions remain unclosed, and their terms could change, according to the report. The available information does not establish a final agreement or confirmed terms.
The distinction between a financing under discussion and a completed investment is significant. The report signals that Isomorphic is seeking additional capital, but it does not establish that investors have committed funds or that any proposed valuation has been agreed. A valuation figure included in an unconfirmed lead could not be verified against the available reporting, so it should not be treated as fact.
Isomorphic’s latest completed financing was a $2.1 billion Series B announced May 12. Thrive Capital led the round, joined by Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund. Reuters reported that the valuation at the time was undisclosed. The size of that round provides a confirmed point of comparison, but it does not settle the amount, valuation or structure of the current talks.
The May financing was intended to support development and deployment of IsoDDE, Isomorphic’s AI drug-design engine, and to expand therapeutic programs toward clinical testing, according to the company’s announcement. That describes the intended use of the proceeds; it is not evidence that a candidate has entered human trials or that a drug has been shown to work.
The company’s clinical progress remains central to assessing what its technology has achieved. President Max Jaderberg said November 2 that Isomorphic remained in preclinical trials and was in its “first innings.” Independent coverage described the company as having no drug in human testing as of November 5. The source material does not confirm a first clinical trial or a timetable for one.
Isomorphic is an Alphabet venture spun out of Google DeepMind. Its focus is to use computational tools to help design medicines, an ambitious application of AI that is distinct from releasing a general-purpose chatbot or language model. The current report concerns company financing; it does not announce a new AI model, a new drug candidate entering clinical testing or a completed strategic transaction.
That distinction matters because funding and scientific progress are related but separate measures. New capital could support continued work on IsoDDE and the company’s therapeutic programs, consistent with the purpose stated for the May round. But a financing, whether proposed or completed, cannot establish that a designed molecule will be safe or effective. Those questions depend on subsequent research and testing, and the available information places Isomorphic’s work before human trials.
The reported talks also arrive after a very large completed round earlier this year, underscoring the scale of investment already associated with the company. The May Series B brought together a mix of private investment firms, Alphabet-linked backers and sovereign or strategic investors. The list of participants is confirmed; the available sources do not specify who, if anyone, is involved in the latest discussions.
The company’s status in preclinical research also sets a practical limit on what can be inferred from the financing report. The stated goal of moving programs toward clinical testing is not the same as a disclosed trial start, and the available material does not identify a medicine or disease program that has reached human participants. Further funding may provide resources for that work, but its timing and results are not established here.
For now, the news is a report of negotiations, not a confirmed transaction or a change in clinical status. Bloomberg’s account is based on people familiar with the matter, while Isomorphic’s most recently announced completed financing remains the May Series B. Until the current talks close and the company discloses terms, their size and implications remain uncertain.
Mason Reed serves as a Staff Writer for Just Right News, where he spearheads the Future Frontiers & Special Projects desk. In an era defined by rapid technological shifts and evolving social landscapes, Mason provides a steady, principled voice, examining the innovations of tomorrow through the lens of traditional American values. His work is most prominently featured in his signature series, “The Next Horizon,” where he explores the intersection of emerging technology, national sovereignty, and the preservation of individual liberty.
A native of San Diego, California, Mason’s worldview was shaped by the unique culture of his hometown. Growing up in a region defined by its strong military presence and its history of maritime industry, he developed a deep-seated respect for the institutions that provide national stability and the entrepreneurial spirit that drives the American economy. This upbringing instilled in him a belief that true progress is not found in discarding the past, but in building upon a foundation of proven principles. His reporting often reflects this San Diego influence, emphasizing the importance of a robust national defense and the necessity of maintaining a competitive edge in the global marketplace.
Now based in San Francisco, Mason operates from the heart of the world’s technological engine. Living and working in the Bay Area provides him with a front-row seat to the advancements—and the ideological challenges—emanating from Silicon Valley. While many in the region embrace a “move fast and break things” mentality, Mason’s reporting serves as a vital counterweight. He offers Just Right News readers a “boots on the ground” perspective, documenting how radical local policies and the concentration of tech power impact the everyday lives of citizens. His proximity to the industry allows him to cut through the marketing jargon of big tech to uncover the real-world implications for privacy, free speech, and the nuclear family.
In his “Future Frontiers” beat, Mason tackles complex subjects ranging from the ethics of artificial intelligence to the burgeoning private space race. He approaches these topics with a healthy skepticism toward centralized bureaucracy, championing instead the decentralized innovations that empower individuals. Through “The Next Horizon,” he highlights the pioneers and thinkers who are working to ensure that the future remains a place where human dignity and constitutional rights are protected. He believes that the rapid pace of change requires more than just technical expertise; it requires a moral compass rooted in the Western tradition.
Throughout his tenure at Just Right News, Mason has remained committed to the idea that the future is something to be shaped, not merely accepted. His writing is characterized by a rigorous defense of American exceptionalism and a belief that the country’s best days lie ahead, provided it remains true to its founding ideals. Whether he is investigating the impact of automation on the American workforce or profiling the next generation of aerospace engineers, Mason Reed ensures that his readers are equipped with the insights they need to navigate a changing world with confidence and clarity.